Photo via The Sydney Morning Herald

First GLP-1 pills for weight loss go on sale in Australia

Read the original at The Sydney Morning Herald ↗
Cite

Rasker, R. (2026, November 19). First GLP-1 pills for weight loss go on sale in Australia. The Sydney Morning Herald. https://www.smh.com.au/national/first-glp-1-pills-for-weight-loss-go-on-sale-in-australia-20261120-p61fub.html?ref=rss&utm_medium=rss&utm_source=rss_feed

Dated from the outlet's own feed. Check the original for its byline.

The Sydney Morning Herald · collected 2026-11-19 · by Rachel Rasker

Quick Summary

Starting Friday, Australians can access the first GLP-1 pills for weight loss, Wegovy and Foundayo, through private prescriptions. These daily oral tablets, manufactured by Novo Nordisk and Lilly respectively, offer significant weight loss and metabolic health benefits but come with high costs ranging from $260 to $395 per month for Wegovy and $250 to $370 for Foundayo. Experts warn of potential risks like malnutrition due to a lack of research on long-term effects.
Written by AI on 2026-11-21, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

As of November 19, 2026, the first GLP-1 pills for weight loss, including Wegovy, are now available in Australia through private prescription. The pills, manufactured by Novo Nordisk, are taken daily and are expected to be used by millions of Australians in the coming years due to their significant health benefits, such as weight loss and improved blood glucose control. However, experts warn that there is a lack of research on the wider effects of these medications, including the risk of malnutrition and nutrient deficiencies, which can lead to serious health concerns like fatigue, nausea, diarrhea, and constipation. Additionally, a PhD candidate at the University of Queensland’s School of Public Health highlighted that common side effects of Wegovy, affecting around 80% of patients, include nausea, vomiting, diarrhea, indigestion, and constipation, with less common but more serious side effects like kidney injury, pancreatitis, and gallbladder problems.

Written for “GLP-1 Pills Available in Australia” on 2026-11-21, grounded in this article and the 1 other(s) covering the same event.

How they differ

2 outlets covered “GLP-1 Pills Available in Australia”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

Sydney Morning HeraldThis outlet19 Nov

Starting Friday, Australians can access the first GLP-1 pills for weight loss, Wegovy and Foundayo, through private prescriptions. These daily oral tablets, manufactured by Novo Nordisk and Lilly respectively, offer significant weight loss and metabolic health benefits but come with high costs ranging from $260 to $395 per month for Wegovy and $250 to $370 for Foundayo. Experts warn of potential risks like…

First GLP-1 pills for weight loss go on sale in Australia (this article)
Daily Mail20 Nov

Wegovy, a weight loss drug available in tablet form, is now sold in Australian pharmacies. The medication, which contains semaglutide, helps reduce appetite and increase feelings of fullness. Common side effects include nausea, vomiting, diarrhea, indigestion, and constipation, affecting about 80% of patients. More serious side effects like kidney injury, pancreatitis, and gallbladder problems are less common but…

'Magic pill' for weight loss now available in Australia: What you need to know about the side effects, how it works and how much it costs →

Compared with similar articles

This article reads unscored and hedges 12% of its claims. Each row says how that neighbour differs.

Story

GLP-1 Pills Available in Australia
Health · 2 article(s) covering the same event. See how they differ ↑
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
17
sentences that state something as happening or true
Uncertain
12%
2 of 17 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
61/100
The Sydney Morning Herald's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
2
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-21 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

The Sydney Morning Herald · 7827 article(s) · 16 correction(s) detected
Running correction rate · 16 correction(s)

Who wrote this

Rachel Rasker
20 article(s) here · 1 carrying a prediction
Millions of Australians are expected to use GLP-1s in the coming years, with the drugs boasting powerful health effects including significant weight loss, improved blood glucose control and other metabolic health benefits. However, experts have warned there is a lack of research into the wider effects of the medications, including the risk of malnutrition, which can cause serious health concerns but go unnoticed as symptoms of nutrient deficiency mimic the side effects of GLP-1s, including fatigue, nausea, diarrhoea and constipation.
The NSW Coroner’s Court on Wednesday was told the parents of the newborn, known as Baby DH, saw signs that “something was seriously wrong” from the first minutes of his life and would have called Triple Zero “almost straight away” if their doula Amy Lou Smith had not been with them.
A Byron doula did not know a woman was carrying twins and could only sense or feel that she was pregnant with one child after “constant mapping” of the mother, a coronial inquest has heard.
As opposed to a planned midwife-led homebirth, a free birth mother may be alone, with a partner or unaccredited support person such as a doula or birth keeper.
This will implement around-the-clock security at 27 hospitals.
A GLP-1 weight-loss tablet has been approved in Australia for the first time, expected to lead to a surge in demand for the sought-after peptide that could hit the market by the end of this year.
Senior doctors at a NSW hospital have demanded the government intervene before an imminent takeover by a Catholic provider they fear will lead to widespread service cuts for expectant mothers and cancer patients.
“Gradually [the writing] will come off, symbolising letting go of your worries.”
About $600 million a year would be needed to fix the state’s shortfall of frontline public mental health staff, a confidential ministerial briefing note says, a figure NSW Health warned could cause reputational damage to the Minns government if revealed.
Emergency departments will brace for a 411 per cent increase in patients aged 85 and over by 2050, the latest Australasian College of Emergency Medicine’s State of Emergency 2026 report revealed.
Also by Rachel Rasker
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 20 articles by Rachel Rasker →

Topics

Australians Foundayo Novo Nordisk TGA Wegovy

Subjects

Australians NORP · 2× Novo Nordisk ORG · 2× Australian NORP · 1× Lilly ORG · 1× TGA ORG · 1× the Pharmaceutical Benefits Scheme ORG · 1×

Narrative

Millions of Australians are expected to use GLP-1s in the coming years, with the drugs boasting powerful health effects including significant weight loss, improved blood glucose control and other metabolic health benefits. However, experts have warned there is a lack of research into the wider effects of the medications, including the risk of malnutrition, which can cause serious health concerns but go unnoticed as symptoms of nutrient deficiency mimic the side effects of GLP-1s, including fatigue, nausea, diarrhoea and constipation.
framing: assertive · carried by 1 article(s) · first seen 2026-11-21
Millions of Australians are expected to use GLP-1s in the coming years, with the drugs boasting powerful health effects including significant weight loss, improved blood glucose control and other metabolic health benefits. However, experts have warned there is a lack of research into the wider effects of the medications, including the risk of malnutrition, which can cause serious health concerns but go unnoticed as symptoms of nutrient deficiency mimic the side effects of GLP-1s, including fatigue, nausea, diarrhoea and constipation.
2026-11-21 · The Sydney Morning Herald
First GLP-1 pills for weight loss go on sale in Australia · assertive framing

Claims (17 extracted, 2 hedged)

Australians can access the first GLP-1 pills for weight loss through private prescription from Friday, likely boosting sales of the popular drugs already used by more than half a million people here. asserted
Australians → access → people
Glucagon-like peptide-1 receptor agonists, or GLP-1s, were previously only available through a weekly injection, while the new Wegovy and Foundayo pills are taken as daily oral tablets. asserted
pills → take → tablets
Millions of Australians are expected to use GLP-1s in the coming years, with the drugs boasting powerful health effects including significant weight loss, improved blood glucose control and other metabolic health benefits. However, experts have warned there is a lack of research into the wider effects of the medications, including the risk of malnutrition, which can cause serious health concerns but go unnoticed as symptoms of nutrient deficiency mimic the side effects of GLP-1s, including fatigue, nausea, diarrhoea and constipation. asserted
symptoms → expect → fatigue
The medications work by curbing appetite, slowing digestion and promoting feelings of fullness. asserted
medications → work → fullness
The Wegovy pill, manufactured by Novo Nordisk, was approved by the TGA earlier this month. asserted
pill → manufacture → TGA
It’s taken every morning on an empty stomach and stays stable at room temperature, unlike the injectable Wegovy, which requires refrigeration. asserted
which → take → refrigeration
The new tablet’s pricing will vary by dose, ranging from about $260 per month for a 1.5mg tablet to $395 a month for 25mg. asserted
pricing → vary → mg
For patients on the lower doses, this works out at less than $10 a day. asserted
this → work → 10
The pill is cheaper than the injectable, which costs between $350 and $500 per month. asserted
which → cost → month
The new tablets are available on shelves from Friday, Novo Nordisk confirmed. asserted
Nordisk → confirm → Friday
Competing manufacturer Lilly won approval for its rival pill Foundayo on Monday, promising availability “in the coming days”. asserted
Lilly → compete → days
However, while doctors could prescribe the drug from the day of approval, stocks are yet to arrive in pharmacies. uncertain
stocks → prescribe → pharmacies
Foundayo is a small-molecule, non-peptide GLP-1 receptor agonist taken as a daily pill at any time, without food or water restrictions. asserted
Foundayo → take → restrictions
It is expected to cost between $250 and $370 per month, depending on the dose and the pharmacy. asserted
It → expect → dose
Users need to be prescribed the pills by their doctor, which may also require an out-of-pocket cost. uncertain
which → need → cost
The Australian government is facing growing pressure to add GLP-1s to the Pharmaceutical Benefits Scheme for weight loss. asserted
government → face → loss
The high price point of the medicines mean they remain out of reach for many with obesity, which disproportionately affects low and middle-income individuals. asserted
which → mean → individuals
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support